TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00909935
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial 2 mcg/kg bolus administered over 10 minutes to achieve the Ramsey sedation score of 4 followed by an infusion of 1.5 mcg/kg/hr, which will run until patient is transferred to recovery area. Up to a further two boluses of 2 mcg/kg may be given to maintain an RSS of 4.
Study: NCT00866554
Drug: administration of a LHRH agonist and Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-month treatment with an LHRH agonist chosen by the treating radiation oncologist and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.
Study: NCT01749969
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:capsules Route of administration: oral
Study: NCT01749969
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:solution or tablet Route of administration: intravenous or oral
Study: NCT00005857
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01300312
Drug: Eperisone hydrochloride
Normalized name: Eperisone hydrochloride
DrugBank: Eperisone (DB08992)
Approvals — FDA: no, EMA: no, PMDA: no
Description: eperisone hydrochloride 50 mg as tablet formulation to be given 3 times daily after meals for 7 to 10 days
Study: NCT00866554
Drug: administration of Bicalutamide, Dutasteride and Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.~Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride~Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered.
Study: NCT01849562
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01854970
Drug: esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with pharyngolaryngeal symptoms will have a clinical evaluation, laryngoscopy, and pharyngoesophageal pH-impedance. Then a treatment by esomeprazole during 8 weeks in the term of which the second clinical evaluation and pH-impedance will be made.
Study: NCT02028533
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00017511
Drug: cevimeline hydrochloride
Normalized name: Cevimeline Hydrochloride
DrugBank: Cevimeline (DB00185)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03740659
Drug: Levofloxacin + Dexamethasone
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin + Dexamethasone ophthalmic solution + dexamethasone 21-phosphate administered twice: 90(±15) min. and 60(±15) min. before limbal paracentesis.
Study: NCT03740659
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin ophthalmic solution (Oftaquix®) administered twice: 90 (±15) min. and 60 (±15) min. before limbal paracentesis).
Study: NCT03740659
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone ophthalmic solution (Tamesad®) administered twice: 90 (±15) min. and 60 (±15) min. before Limbal paracentesis.
Study: NCT01394211
Drug: anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02114463
Drug: ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2% ropivacaine
Study: NCT03498170
Drug: Itraconazole 200 mg
Normalized name: itraconazole 200 MG
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of itraconazole
Study: NCT03432780
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01394211
Drug: pazopanib hydrochloride
Normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02304419
Drug: Galunisertib
Normalized name: Galunisertib
DrugBank: Galunisertib (DB11911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT00380705
Drug: MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00269880
Drug: Abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.
Study: NCT01453933
Drug: raltegravir
Normalized name: Raltegravir
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Switch of lopinavir/ritonavir to raltegravir 400 mg BID (duration 8 weeks)
Study: NCT02779608
Drug: intraperitoneal docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One peritoneal access port will be implanted in subcutaneous space of patients' abdominal wall after laparoscopic exploration.Then intraperitoneal docetaxel in 1litre normal saline will be administered through the port
Study: NCT02779608
Drug: oral S-1
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg/m² twice daily on day 1-14 every 3 weeks
Study: NCT02724085
Drug: TP-271
Normalized name: TP-271
DrugBank: TP-271 (DB15040)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens. It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
Study: NCT05561036
Drug: Saline Solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline solution
Study: NCT02914522
Drug: Filgotinib
Normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Tablet(s) administered orally once daily
Study: NCT01789710
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants who are medically eligible to take Bupropion will receive this study medication one week prior to their smoking quit date.
Study: NCT01789710
Drug: Nicotine replacement therapy
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will receive two forms of nicotine replacement therapy - nicotine patches and a rescue method (either gum or lozenge).
Study: NCT02914522
Drug: PTM filgotinib
Normalized name: Nilotinib
DrugBank: Filgotinib (DB14845)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet(s) administered orally once daily
Study: NCT00171002
Drug: valsartan/amlodipine
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01187628
Drug: Fosrenol (Lanthanum Carbonate, BAY77-1931)
Normalized name: Fosrenol
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily dose: 750-2250mg/day,(270-750mg each 3 times a day) for 52 weeks.
Study: NCT00607087
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
Study: NCT00607087
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
Study: NCT00607087
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
Study: NCT00279916
Drug: Triamcinolone acetonide nasal spray
Normalized name: triamcinolone acetonide Metered Dose Nasal Spray
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects aged 12 years or older received 2 metered sprays in each nostril once daily (55 micrograms/spray) (total daily dose 220 micrograms).~Subjects younger than 12 years old received received 1 metered spray in each nostril once daily (55 micrograms/spray) (total daily dose 110 micrograms).
Study: NCT02874326
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004141
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004141
Drug: dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004141
Drug: Granulocyte-macrophage colony-stimulating factor
Normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01141322
Drug: Ursodeoxycholic Acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ursodeoxycholic acid 13-15 mg/kg BW/day into 3 divided doses after meal till endpoint or the 8th week.
Study: NCT03292315
Drug: Semaglutide 1MG Injection [Ozempic]
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once weekly injection of 1mg of Semaglutide.
Study: NCT00633360
Drug: Drospirenone and ethinyl estradiol
Normalized name: DROSPIRENONE AND ETHINYL ESTRADIOL KIT
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once daily by mouth
Study: NCT03245541
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab will be given 750 mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q14 days beginning D1. Four doses of durvalumab will be administered on the Q14 day schedule. Subsequently Durvalumab will continue as maintenance 1500mg, intravenously (IV) over 60 minutes (+/- 5 minutes), Q28 days up to 1 year or until progression (11 doses), unacceptable toxicity or other reason. If a patient undergoes resection, they will resume durvalumab once appropriately healed from surgery (approximately 4-8 weeks) at discretion of treating medical oncologist.
Study: NCT02219737
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IVPB
Study: NCT02219737
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IVPB
Study: NCT02219737
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02219737
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03749213
Drug: Icotinib
Normalized name: icotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks as neoadjuvant therapy before surgery and for 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
Study: NCT01505114
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300-mg tablet, once daily, from Week 0 through Week 48
Study: NCT01505114
Drug: Emtricitabine
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200-mg capsule, once daily, from Week 0 through Week 48
Study: NCT01505114
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300-mg tablet, once daily, from Week 0 through Week 48
Study: NCT02517307
Drug: Hyperinsulinemic euglycemic clamp
Normalized name: CLAMP
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of insulin at at 40 mU/m2/min for 5 hours. Blood glucose will be monitored every 5 min during the insulin infusion and euglycemia will be maintained throughout the clamp by infusing 20% dextrose at a variable rate.
Study: NCT00193297
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02955368
Drug: DP-R212
Normalized name: DP-303c
DrugBank: DP-303c (DB17212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP-R212 + C1-R212 placebo + C2-R212 placebo
Study: NCT02955368
Drug: C1-R212
Normalized name: C1-INH
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP-R212 placebo + C1-R212 + C2-R212 placebo
Study: NCT00193297
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00193297
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02955368
Drug: C2-R212
Normalized name: Gentamicin C2
DrugBank: Gentamicin C2 (DB17884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP-R212 placebo + C1-R212 placebo + C2-R212
Study: NCT00798525
Drug: Argatroban
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatra (Argatroban) will be diluted to 0.6 mg/ml and 0.5 µg/kg/min will be administered continuously in patients without liver disfunction. In patients with liver disfunction, defined by a bilirubin of \> 4mg/dl, argatroban will be administered as a continuous infusion of 0,25 µg/kg/min with a final concentration of 0,3 mg/ml.
Study: NCT00798525
Drug: Lepirudin
Normalized name: Lepirudin
DrugBank: Lepirudin (DB00001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Refludan (Lepirudin) will be diluted to a final concentration of 0.1mg/ml and initiated as a continuous infusion of 5µg/kg/h in patients with continuous renal replacement therapy. In patients with moderate renal impairment (Creatinine ≥1,3 mg/dl) a final concentration 0,2 mg/ml of will be used to provide continuous infusion of 10 µg/kg/h. Patients without renal impairment (Creatinine \< 1,3 mg/dl) will receive a continuous infusion of 50 µg/kg/h by a final concentration of 1 mg/ml of Lepirudin.
Study: NCT00079560
Drug: dronabinol
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dronabinol to prevent development of marijuana withdrawal
Study: NCT04346004
Drug: Iron isomaltoside
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in Iron isomaltoside group are administered IV Iron maltoside diluted in 100 cc normal saline (20mg/kg, maximum dose: 1g) \& IM Vitamin B12 (1mg) 1 day before surgery.
Study: NCT03152188
Drug: FMT
Normalized name: [18F]FMT
DrugBank: 6-[18F]-Fluoro-L-m-tyrosine (DB17621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fifteen FMT Openbiome capsules administered at the same time
Study: NCT02826876
Drug: Topical use
Normalized name: Psoralens for topical use
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical use of Ropivacaine in laparoscopic surgery
Study: NCT01235507
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 m/kg (maximum 800 mg) intravenously every 4 weeks for a total of 6 infusions
Study: NCT00926185
Drug: Lifitegrast
Normalized name: Lifitegrast
DrugBank: Lifitegrast (DB11611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ophthalmic Solution
Study: NCT02770248
Drug: Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03893032
Drug: Modafinil 200mg
Normalized name: MODAFINIL 200MG TAB
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single 200 mg dose
Study: NCT03893032
Drug: mixed amphetamine salts
Normalized name: mixed amphetamine salts 5 MG Oral Tablet
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single 10 mg dose
Study: NCT00002675
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002675
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002675
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002675
Drug: mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002675
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00625079
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the dose of sildenafil will be 20mg three times per day (orally)
Study: NCT01553019
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 300 mg/m2 infused over 30 minutes, weekly during proton therapy.
Study: NCT01019070
Drug: BMS-650032
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsules, Oral, 200 mg, BID, 7 Days
Study: NCT00638690
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Four 250-mg tablets once daily until disease progression
Study: NCT00638690
Drug: Prednisone/prednisolone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg twice daily until disease progression
Study: NCT00310154
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00310154
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00043082
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous q 4 weeks
Study: NCT02454894
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: surface anesthesia with lidocaine
Study: NCT00349024
Drug: polyvinylpyrrolidone-sodium hyaluronate gel
Normalized name: sodium hyaluronate Ophthalmic Gel
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01045876
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of 8 mg of Dexamethasone intravenously at induction of anesthesia
Study: NCT00719823
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maraviroc 150mg, 300 mg or 600 mg twice daily administered orally with or without food in combination with other antiretroviral agents. The recommended dose of Maraviroc differs based on concomitant medications due to drug interactions as outlined in the Prescribing Information.
Study: NCT00603356
Drug: OSI-930 and erlotinib
Normalized name: OSI-930
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OSI-930 administered daily in combination with Erlotinib at increasing doses until disease progression or unacceptable toxicity
Study: NCT03659201
Drug: Neosil
Normalized name: hyoscyamine sulfate Disintegrating Oral Tablet [Neosol]
DrugBank: Hyoscyamine (DB00424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, during only 12 weeks.
Study: NCT02487095
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan (in combination with VX-970 (M6620) administered by intravenous (IV) Days 1-5 in a 21 day cycle, until disease progression or development of intolerable side effects.
Study: NCT00605904
Drug: Acamprosate
Normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: orally administered tablet, 333mg, three times daily for a minimum of 2 weeks (14 days)
Study: NCT00605904
Drug: Yohimbine
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of yohimbine (0.4 mg/kg) administered once over 10 minutes
Study: NCT00605904
Drug: mCPP
Normalized name: MCPP
DrugBank: m-Chlorophenylpiperazine (DB12110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of mCPP (0.05 mg/kg) over 10 minutes, two times, for a total of 0.1 mg/kg
Study: NCT00605904
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion of 0.9% sodium chloride solution over 10 minutes, three times during the study (2 times for the Saline Infusion milestone, and one time immediately following the Yohimbine Infusion milestone)
Study: NCT03503630
Drug: COMPOUND 2055269
Normalized name: Blackburn Compound
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COMPOUND 2055269 to be given every 2 weeks with chemotherapy for 6 cycles
Study: NCT00961636
Drug: ER niacin (+) laropiprant (ERN/LRPT)
Normalized name: niacin Extended Release Oral Capsule
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks
Study: NCT00961636
Drug: ER niacin (+) laropiprant (ERN/LRPT)
Normalized name: niacin Extended Release Oral Capsule
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks.
Study: NCT00961636
Drug: Extended-release niacin (ERN)
Normalized name: niacin Extended Release Oral Capsule
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 1g tablets ERN (2g total) once daily for 12 weeks.
Study: NCT02619266
Drug: Megestrol Acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol Acetate 160mg tablet
Study: NCT02619266
Drug: Placebo(Megestrol Acetate)
Normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starch pill manufactured to mimic Megestrol Acetate 160mg tablet